# Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

> **NCT06015035** · PHASE2 · COMPLETED · sponsor: **Tang-Du Hospital** · enrollment: 17 (actual)

## Conditions studied

- Sintilimab and Anlotinib in Combination With Chemotherapy

## Interventions

- **DRUG:** Sintilimab and anlotinib in combination with chemotherapy

## Key facts

- **NCT ID:** NCT06015035
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015035, "Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06015035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*